Our findings highlight the idea that chemokine receptors (e.g., CCR1, CCR2, CCR3) and signaling molecules that control their expression/function (e.g., caveolin-1, MEK/ERK, Src/Lyn) are promising targets for novel treatments for fibrotic diseases such as SSc. The gene discussed is CCR3; the disease is systemic sclerosis.